Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing for N2451R105 since 12/18/2024, newest first.
| Filer | % of Class | Filed | |
|---|---|---|---|
|
Hothum Mathias
13D/A
Amendment 3
|
0% |
12/12/2025
Event 12/10/2025
|
|
| MH-LT-Investments GmbH | 0% | ||
| Dr. Matthias Hothum | 0% | ||
|
dievini Hopp BioTech holding GmbH & Co KG
13D/A
Amendment 9
|
0% |
12/12/2025
Event 12/10/2025
|
|
| dievini Hopp BioTech holding GmbH & Co. KG | 0% | ||
| DH-LT-Investments GmbH | 0% | ||
| DH-Capital GmbH & Co. KG | 0% | ||
| OH Beteiligungen GmbH & Co. KG | 0% | ||
| Dietmar Hopp | 0% | ||
| Oliver Hopp | 0% | ||
| Daniel Hopp | 0% | ||
| DHFS II Holding GmbH & Co. KG | 0% | ||
| Zweite DH Verwaltungs GmbH | 0% | ||
| KfW 13D/A Amendment 7 | 0% |
12/12/2025
Event 12/10/2025
|
|
| GSK plc 13D/A Amendment 1 | 0% |
12/5/2025
Event 12/3/2025
|
|
| GSK plc 13D | 74.0% |
8/13/2025
Event 8/7/2025
|
|
| KfW 13D/A Amendment 6 | 50.1% |
8/1/2025
Event 8/1/2025
|
|
|
dievini Hopp BioTech holding GmbH & Co KG
13D/A
Amendment 8
|
36.7% |
6/16/2025
Event 6/12/2025
|
|
| dievini Hopp BioTech holding GmbH & Co. KG | 31.3% | ||
| DH-LT-Investments GmbH | 3.9% | ||
| DH-Capital GmbH & Co. KG | 31.3% | ||
| OH Beteiligungen GmbH & Co. KG | 31.3% | ||
| Dietmar Hopp | 36.7% | ||
| Oliver Hopp | 31.3% | ||
| Daniel Hopp | 31.3% | ||
| DHFS II Holding GmbH & Co. KG | 3.9% | ||
| Zweite DH Verwaltungs GmbH | 1.5% |
| Period | Filings | Shares, Excl. Options | Value, Excl. Options |
|---|---|---|---|
| 2025 Q4 | 61 | 5.93 M | $26.6 M |
| 2025 Q3 | 102 | 20.0 M | $107 M |
| 2025 Q2 | 98 | 11.9 M | $63.7 M |
| 2025 Q1 | 89 | 7.87 M | $21.8 M |
| 2024 Q4 | 81 | 7.86 M | $26.6 M |
| 2024 Q3 | 89 | 11.1 M | $36.8 M |
| 2024 Q2 | 97 | 14.5 M | $49.3 M |
| 2024 Q1 | 99 | 19.3 M | $60.4 M |
| 2023 Q4 | 103 | 23.2 M | $97.5 M |
| 2023 Q3 | 94 | 33.7 M | $230 M |
| 2023 Q2 | 97 | 35.7 M | $373 M |
| 2023 Q1 | 90 | 36.7 M | $256 M |
| 2022 Q4 | 96 | 11.9 M | $72.1 M |
| 2022 Q3 | 95 | 7.15 M | $56.4 M |
| 2022 Q2 | 105 | 8.41 M | $114 M |
| 2022 Q1 | 131 | 14.4 M | $283 M |
| 2021 Q4 | 135 | 14.9 M | $512 M |
| 2021 Q3 | 145 | 13.7 M | $750 M |
| 2021 Q2 | 150 | 13.9 M | $1.02 B |
| 2021 Q1 | 107 | 14.1 M | $1.28 B |
| 2020 Q4 | 81 | 10.5 M | $852 M |
| 2020 Q3 | 52 | 7.61 M | $355 M |
| 2020 Q2 | 1 | 108 | $8.00 k |
| 2020 Q1 | 1 | 108 | $8.00 k |
| 2019 Q4 | 1 | 108 | $8.00 k |
| 2019 Q3 | 1 | 108 | $8.00 k |
| 2019 Q2 | 1 | 108 | $8.00 k |
| 2019 Q1 | 1 | 108 | $8.00 k |